4.6 Article

Evaluation of the impact of repeated intravenous phage doses on mammalian host-phage interactions

Related references

Note: Only part of the references are listed.
Review Infectious Diseases

Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review

Saartje Uyttebroek et al.

Summary: According to the latest reports from WHO, the incidence of antibiotic-resistant bacterial infections is increasing worldwide, leading to higher morbidity and mortality rates and putting a strain on healthcare systems. The development of new antibiotics is costly and time-consuming, prompting scientists to explore alternative antimicrobial strategies. Therapeutic administration of bacteriophages, or phages, has gained popularity as a promising concept. However, the widespread implementation of phage therapy in routine clinical practice is constrained by the scarcity of safety and efficacy data collected based on strict clinical trial regulations.

LANCET INFECTIOUS DISEASES (2022)

Article Infectious Diseases

Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial

Lorenz Leitner et al.

Summary: This study aimed to determine the effectiveness of intravesical bacteriophage therapy in treating UTIs. Findings showed that bacteriophage therapy was non-inferior to standard antibiotic treatment, but not superior to placebo bladder irrigation in terms of efficacy or safety. The safety profile of bacteriophages appears to be favorable, suggesting potential for further large-scale clinical studies on their role in UTI treatment.

LANCET INFECTIOUS DISEASES (2021)

Review Oncology

Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins

Nicole L. Jarvi et al.

Summary: The subcutaneous route of administration provides convenient delivery, but may lead to enhanced immunogenicity; unwanted antibody response can impact pharmacokinetics and efficacy of biologics; careful consideration is needed for the unique immunogenic challenges associated with subcutaneous protein administration.

BIODRUGS (2021)

Article Immunology

Clinical Experience of Personalized Phage Therapy Against Carbapenem-Resistant Acinetobacter baumannii Lung Infection in a Patient With Chronic Obstructive Pulmonary Disease

Xin Tan et al.

Summary: A case of an 88-year-old Chinese man with hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii was successfully treated with a personalized lytic pathogen-specific single-phage preparation nebulized continuously for 16 days, in combination with tigecycline and polymyxin E. The treatment was well tolerated and led to pathogen clearance and clinical improvement in lung function for the patient.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Article Biochemistry & Molecular Biology

Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection

Rebekah M. Dedrick et al.

Summary: In a case study, it was found that bacteriophage therapy was effective in reducing the infectious burden of a refractory bacterial infection in an immunocompetent patient, but its efficacy was limited as the patient developed neutralizing antibodies against the phages after two months.

NATURE MEDICINE (2021)

Review Virology

The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies

Dan Liu et al.

Summary: Phage therapy has garnered renewed interest due to increasing rates of antibiotic resistant bacteria infections. Safety and toxicity data associated with phage therapy in animals and humans have been systematically reviewed from English language publications between 2008-2021. While some adverse events were found in relation to phage therapy, serious events were extremely rare, highlighting the need for structured safety and tolerability endpoints in the therapeutic use of phages. Comprehensive and standardized reporting of potential toxicities associated with phage therapy has generally been lacking in published literature.

VIRUSES-BASEL (2021)

Article Immunology

Pharmacokinetics and Pharmacodynamics of a Novel Virulent Klebsiella Phage Kp_Pokalde_002 in a Mouse Model

Gunaraj Dhungana et al.

Summary: The study demonstrated that oKp_Pokalde_002 rapidly distributed in the mouse model and significantly reduced bacterial count in the blood and other organs within 24 hours, showing promising therapeutic potential for carbapenem-resistant Klebsiella pneumoniae infections.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)

Article Medicine, Research & Experimental

Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies

Shufang Liu et al.

Summary: Research has shown the significant impact of molecular charge on antibody PK, with engineered complementarity-determining regions (CDRs) of trastuzumab leading to variants with increased positive charge accumulation in tissues. Whole-body PK experiments revealed a bell-shaped relationship between systemic exposure and Fv charge, and positive charge variants exhibited superior accumulation in well-perfused organs.
Correction Microbiology

Safety of bacteriophage therapy in severe Staphylococcus aureus infection (vol 13, pg 876, 2020)

Aleksandra Petrovic Fabijan et al.

NATURE MICROBIOLOGY (2020)

Article Infectious Diseases

Pharmacokinetics/pharmacodynamics of antipseudomonal bacteriophage therapy in rats: a proof-of-concept study

Y. W. Lin et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

Review Microbiology

Antimicrobial Resistance in ESKAPE Pathogens

David M. P. De Oliveira et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

Article Biochemical Research Methods

Standardized bacteriophage purification for personalized phage therapy

Tiffany Luong et al.

NATURE PROTOCOLS (2020)

Article Biochemistry & Molecular Biology

Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus

Rebekah M. Dedrick et al.

NATURE MEDICINE (2019)

Review Veterinary Sciences

Nonhuman primate species as models of human bacterial sepsis

Lingye Chen et al.

LAB ANIMAL (2019)

Review Virology

Interactions between Bacteriophage, Bacteria, and the Mammalian Immune System

Jonas D. Van Belleghem et al.

VIRUSES-BASEL (2019)

Review Immunology

A bacteriophages journey through the human body

Jeremy J. Barr

IMMUNOLOGICAL REVIEWS (2017)

Review Biochemistry & Molecular Biology

Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes

Mauro Cataldi et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Article Multidisciplinary Sciences

Mammalian Host-Versus-Phage immune response determines phage fate in vivo

Katarzyna Hodyra-Stefaniak et al.

SCIENTIFIC REPORTS (2015)

Article Immunology

Phage Neutralization by Sera of Patients Receiving Phage Therapy

Marzanna Lusiak-Szelachowska et al.

VIRAL IMMUNOLOGY (2014)

Review Chemistry, Multidisciplinary

The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage

Amr S. Abu Lila et al.

JOURNAL OF CONTROLLED RELEASE (2013)

Article Multidisciplinary Sciences

Purification and Visualization of Lipopolysaccharide from Gram-negative Bacteria by Hot Aqueous-phenol Extraction

Michael R. Davis et al.

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2012)

Article Microbiology

Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models

Birendra R. Tiwari et al.

JOURNAL OF MICROBIOLOGY (2011)

Article Biotechnology & Applied Microbiology

The RAST server: Rapid annotations using subsystems technology

Ramy K. Aziz et al.

BMC GENOMICS (2008)

Article Biochemical Research Methods

Immunological factors that affect the in vivo fate of T7 phage in the mouse

AS Srivastava et al.

JOURNAL OF VIROLOGICAL METHODS (2004)